What SEC filings does Biodesix, Inc. submit to the SEC?

Biodesix, Inc. (BDSX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BDSX?

A Form 4 for BDSX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Biodesix, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BDSX?

The 10-K is Biodesix, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BDSX SEC filings directly on EDGAR?

You can view all historical Biodesix, Inc. filings on the SEC EDGAR company page for BDSX. Each filing card on this page links directly to the original SEC document.

How often does Biodesix, Inc. file with the SEC?

Biodesix, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BDSX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BDSX SEC Filing News — Biodesix, Inc.

Latest SEC filings for Biodesix, Inc. (BDSX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy,…

Sector: Healthcare Industry: Diagnostics & Research Market Cap: $246.9M CIK: 1439725

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BDSX currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 2 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

BDSX Filing Activity Snapshot 2026-02-11 — 2026-10-02

Insider Transactions (Form 4)

2 buys vs 7 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$665.9K

SCHULER JACK W (10% Owner) · 2026-08-12

27,600 shares · Form 4

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Biodesix, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 7 open-market sale, 3 option exercise and 2 open-market purchase. 9 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×3: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Option exercise Tax / Compensation Filing 2026-10-02

BDSX insider Form 4 filed for equity award, exercise, or tax withholding

PATIENCE JOHN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,360	—	—
`M`	Option exercise derivative · Restricted Stock Units	1,360	—	—

Filing: Form 4 (Insider Transaction) Insider: PATIENCE JOHN (Director) Shares: 1,360

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-13

BDSX insider SCHULER JACK W (10% Owner) bought 15,000 shares (~$367.0K)

SCHULER JACK W, listed as 10% Owner at BIODESIX INC, reported an open-market purchase of 15,000 BDSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	15,000	$24.47	$367.0K

Filing: Form 4 (Insider Transaction) Insider: SCHULER JACK W (10% Owner) Shares: 15,000 Est. Value: $367.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-12

BDSX insider SCHULER JACK W (10% Owner) bought 27,600 shares (~$665.9K)

SCHULER JACK W, listed as 10% Owner at BIODESIX INC, reported an open-market purchase of 27,600 BDSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	13,900	$24.25	$337.0K
`P`	Open-market purchase	13,700	$24.01	$328.9K

Filing: Form 4 (Insider Transaction) Insider: SCHULER JACK W (10% Owner) Shares: 27,600 Est. Value: $665.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-07-02

BDSX insider Form 4 filed for equity award, exercise, or tax withholding

PATIENCE JOHN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,361	—	—
`M`	Option exercise derivative · Restricted Stock Units	1,361	—	—

Filing: Form 4 (Insider Transaction) Insider: PATIENCE JOHN (Director) Shares: 1,361

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-04-02

BDSX insider Form 4 filed for equity award, exercise, or tax withholding

PATIENCE JOHN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,361	—	—
`M`	Option exercise derivative · Restricted Stock Units	1,361	—	—

Filing: Form 4 (Insider Transaction) Insider: PATIENCE JOHN (Director) Shares: 1,361

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-23

BDSX insider Pestano Gary Anthony (Chief Development Officer) sold 556 shares (~$7.1K)

Pestano Gary Anthony, listed as Chief Development Officer at BIODESIX INC, reported an open-market sale of 556 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,528	—	—
`S`	Open-market sale	556	$12.78	$7.1K
`M`	Option exercise derivative · Restricted Stock Units	1,528	—	—

Filing: Form 4 (Insider Transaction) Insider: Pestano Gary Anthony (Chief Development Officer) Shares: 556 Est. Value: $7.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-23

BDSX insider O'Kane Kieran (Chief Commercial Officer) sold 535 shares (~$6.8K)

O'Kane Kieran, listed as Chief Commercial Officer at BIODESIX INC, reported an open-market sale of 535 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,469	—	—
`S`	Open-market sale	535	$12.78	$6.8K
`M`	Option exercise derivative · Restricted Stock Units	1,469	—	—

Filing: Form 4 (Insider Transaction) Insider: O'Kane Kieran (Chief Commercial Officer) Shares: 535 Est. Value: $6.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-23

BDSX insider Cowie Robin Harper (CFO, Sec'y & Treasurer) sold 535 shares (~$6.8K)

Cowie Robin Harper, listed as CFO, Sec'y & Treasurer at BIODESIX INC, reported an open-market sale of 535 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,469	—	—
`S`	Open-market sale	535	$12.78	$6.8K
`M`	Option exercise derivative · Restricted Stock Units	1,469	—	—

Filing: Form 4 (Insider Transaction) Insider: Cowie Robin Harper (CFO, Sec'y & Treasurer) Shares: 535 Est. Value: $6.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-23

BDSX insider Vazquez Chris (Chief Accounting Officer) sold 211 shares (~$2.7K)

Vazquez Chris, listed as Chief Accounting Officer at BIODESIX INC, reported an open-market sale of 211 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	563	—	—
`S`	Open-market sale	211	$12.78	$2.7K
`M`	Option exercise derivative · Restricted Stock Units	563	—	—

Filing: Form 4 (Insider Transaction) Insider: Vazquez Chris (Chief Accounting Officer) Shares: 211 Est. Value: $2.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-23

BDSX insider Hutton Scott (Director, President & CEO) sold 1,490 shares (~$19.0K)

Hutton Scott, listed as Director, President & CEO at BIODESIX INC, reported an open-market sale of 1,490 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	4,844	—	—
`S`	Open-market sale	1,490	$12.78	$19.0K
`M`	Option exercise derivative · Restricted Stock Units	4,844	—	—

Filing: Form 4 (Insider Transaction) Insider: Hutton Scott (Director, President & CEO) Shares: 1,490 Est. Value: $19.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-11

BDSX insider O'Kane Kieran (Chief Commercial Officer) sold 584 shares (~$5.9K)

O'Kane Kieran, listed as Chief Commercial Officer at BIODESIX INC, reported an open-market sale of 584 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,600	—	—
`S`	Open-market sale	584	$10.08	$5.9K
`M`	Option exercise derivative · Restricted Stock Units	73	—	—
`M`	Option exercise derivative · Restricted Stock Units	1,527	—	—

Filing: Form 4 (Insider Transaction) Insider: O'Kane Kieran (Chief Commercial Officer) Shares: 584 Est. Value: $5.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-11

BDSX insider Vazquez Chris (Chief Accounting Officer) sold 101 shares (~$1.0K)

Vazquez Chris, listed as Chief Accounting Officer at BIODESIX INC, reported an open-market sale of 101 BDSX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	263	—	—
`S`	Open-market sale	101	$10.08	$1.0K
`M`	Option exercise derivative · Restricted Stock Units	28	—	—
`M`	Option exercise derivative · Restricted Stock Units	235	—	—

Filing: Form 4 (Insider Transaction) Insider: Vazquez Chris (Chief Accounting Officer) Shares: 101 Est. Value: $1.0K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Biodesix, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-02-23

BDSX Form 144 filed for proposed insider sale by Hutton Scott (1,490 shares) ~$19.0K

Hutton Scott filed a Form 144 with the SEC indicating intent to sell BDSX (BIODESIX INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Hutton Scott Shares: 1,490 Est. Value: $19.0K

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Biodesix, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

BDSX filed 8-K — material company event

BIODESIX INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-20

BDSX filed 8-K — material company event

BIODESIX INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-04

BDSX filed 8-K — material company event

BIODESIX INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-02-26

BDSX filed 8-K — material company event

BIODESIX INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Biodesix, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

BDSX filed Quarterly Report (10-Q)

BIODESIX INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-04

BDSX filed Quarterly Report (10-Q)

BIODESIX INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-02-26

BDSX filed Annual Report (10-K)

BIODESIX INC filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify Biodesix, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BDSX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — BDSX SEC Filings

More Tools for BDSX

BDSX Full Stock Analysis BDSX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper BDSX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BDSX stock analysis page.

BDSX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer